Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B

Journal of Hepatology
Franziska RinkerMarkus Cornberg

Abstract

Treatment with nucleos(t)ide analogues (NA) leads to hepatitis B virus (HBV) DNA suppression in most patients with chronic hepatitis B (CHB), but HBV surface antigen (HBsAg) loss rates are low. Upon NA discontinuation, HBV DNA can return rapidly with ensuing alanine aminotransferase flares and induction of cytokines. Several studies reported higher HBsAg loss rates after stopping therapy, but at present it is unclear if cell-mediated immune responses are altered after treatment discontinuation. The aim of this study was to characterise T cell responses during the early phase of virological relapse, following discontinuation of NA therapy in HBeAg-negative patients. A total of 15 HBeAg-negative patients with CHB on long-term NA treatment were included in a prospective study and subjected to structured NA discontinuation. T cell responses were studied at the end of NA therapy and 4, 8 and 12 weeks thereafter. The T cell phenotype of patients with CHB on long-term NA therapy was markedly different compared to healthy individuals, but was only slightly altered after discontinuation of therapy. T cells from patients with HBsAg loss expressed low levels of KLRG1 and PD-1 at all time-points and high levels of Ki-67 and CD38 at week 12...Continue Reading

Citations

Jul 23, 2019·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·Lu NingKangxian Luo
Sep 4, 2019·Nature Reviews. Gastroenterology & Hepatology·Yun-Fan Liaw
Jul 10, 2018·The Journal of Infectious Diseases·Christoph Höner Zu SiederdissenMarkus Cornberg
Dec 18, 2019·Liver International : Official Journal of the International Association for the Study of the Liver·Grace L-H WongVincent W-S Wong
Feb 26, 2020·Cells·Margarita Papatheodoridi, George Papatheodoridis
Mar 13, 2020·Expert Review of Gastroenterology & Hepatology·Emilia Hadziyannis, Stephanos Hadziyannis
May 12, 2019·Current Treatment Options in Gastroenterology·Hannah M Lee, Bubu A Banini
Sep 25, 2019·Nature Reviews. Gastroenterology & Hepatology·Mala K Maini, Alice R Burton
Jan 9, 2019·Nature Reviews. Gastroenterology & Hepatology·Jordan J Feld, Adam J Gehring
Feb 6, 2020·Journal of the Chinese Medical Association : JCMA·Chien-Wei SuJaw-Ching Wu
Oct 4, 2020·Chinese Medical Journal·Xiao-Qi Yu, Xin-Xin Zhang
Aug 12, 2020·Gastroenterología y hepatología·Manuel RodríguezJavier García-Samaniego
Nov 12, 2019·Journal of Hepatology·Upkar S Gill, Neil E McCarthy
Aug 19, 2020·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Yun-Fan Liaw
Dec 6, 2020·Journal of Hepatology·Mireia García-LópezSofía Pérez-Del-Pulgar
May 7, 2021·Journal of Hepatology·Thomas Berg, Pietro Lampertico
Jul 24, 2021·Hepatology International·Jia-Horng KaoMan-Fung Yuen
Oct 1, 2021·Frontiers in Immunology·Sara Ferrando-MartinezScott H Robbins
Dec 23, 2021·Liver International : Official Journal of the International Association for the Study of the Liver·Yen-Chun LiuYun-Fan Liaw

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.